Research Topics
Genomes and Genes | David G HicksSummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challengeDavid G Hicks
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Appl Immunohistochem Mol Morphol 19:506-8. 2011....- Immunohistochemistry in the diagnostic evaluation of breast lesionsDavid G Hicks
University of Rochester Medical Center, Elmwood Avenue, Rochester, NY 14642, USA
Appl Immunohistochem Mol Morphol 19:501-5. 2011..This article will briefly review some of the more common circumstances in which IHC has been shown to be useful in diagnostic breast pathology... 
TLE3 as a candidate biomarker of response to taxane therapySwati A Kulkarni
Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Breast Cancer Res 11:R17. 2009..The addition of taxanes (Ts) to chemotherapeutic regimens has not demonstrated a consistent benefit in early-stage breast cancer. To date, no clinically relevant biomarkers that predict T response have been identified...- The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrenceDavid G Hicks
Clarient Inc, Aliso Veijo, California, USA
BMC Cancer 10:108. 2010..Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients... - Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testingDavid G Hicks
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY 14642, USA
Arch Pathol Lab Med 132:1008-15. 2008..In all 4 trials, disease-free survival and overall survival were significantly improved with adjuvant trastuzumab (36%-52% and 33%-41%, respectively), and improvements were observed in all patient subgroups... - Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handlingDavid G Hicks
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
J Natl Cancer Inst Monogr 2011:43-5. 2011..The quality of archival tissue samples for future biomarker research will also benefit... - The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational researchD G Hicks
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA
Biotech Histochem 87:14-7. 2012..Inaccurate results owing to compromised tissue quality can lead to false positive or false negative results with therapeutic consequences that can harm patients and affect their eventual outcome... - HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic toolsDavid G Hicks
Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Am J Clin Pathol 129:263-73. 2008..Rigorous quality control and standardization of the testing process, from the handling of tissue samples to interpretation and reporting of results, are essential for achieving accurate and reproducible assay results... - Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherol-associated protein in estrogen-receptor-positive breast carcinomasSharlin Johnykutty
Department of Pathology and Laboratory Medicine, University of Rochester Medical School, Rochester, NY 14642, USA
Mod Pathol 22:770-5. 2009.... - Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritisChristopher T Ritchlin
Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
J Clin Invest 111:821-31. 2003..This leads to osteoclastogenesis at the erosion front and in subchondral bone, resulting in a bidirectional assault on psoriatic bone... - A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancerPing Tang
Department of Pathology, University of Rochester of Rochester Medical Center, New York, USA
Cancer Invest 28:978-82. 2010..926 (mitosis) -2.408 (PR) -1.061 (HER2) + 7.051 (luminal A) + 29.172 (luminal B) predicts RS with an R² of 0.65. In conclusion, PR negativity, luminal B subtype, tubal formation, and mitosis are strongly correlated with a higher RS... - Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?Ping Tang
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Diagn Mol Pathol 18:125-32. 2009..We also propose a standardized IHC-based molecular classification, in the hope that it will promote more uniform large multicenter studies, and facilitate its clinical application... - HER2 amplification, overexpression and score criteria in esophageal adenocarcinomaYingchuan Hu
Department of Pathology, University of Rochester, Rochester, NY, USA
Mod Pathol 24:899-907. 2011..A modified two-step model for esophageal adenocarcinoma HER2 testing is recommended for clinical esophageal adenocarcinoma HER2 trial... - Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progressionSanjib Banerjee
Department of Surgery, University of Rochester Medical Center, Rochester, New York 14642, USA
Cancer Res 71:318-27. 2011..Thus, our data demonstrate a novel immune escape and tumor growth-supporting mechanism mediated by soluble Hsp27 that may be operative in human breast cancer... - Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)Ya Hui Chiu
Allergy Immunology and Rheumatology Division, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA
J Bone Miner Res 27:79-92. 2012..Taken together, these data show that DC-STAMP is a potential OCP biomarker in inflammatory arthritis. Moreover, in addition to its effect on cell fusion, DC-STAMP dynamically regulates cell signaling during osteoclastogenesis... - GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumorHiroshi Miyamoto
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Hum Pathol 43:2033-40. 2012..Loss of GATA binding protein 3 was associated with high-grade and/or muscle-invasive tumors, whereas strong expression was an independent predictor of poor prognosis... 
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical studySarah M Short
Department of Anatomic and Clinical Pathology L25, Cleveland, Ohio, USA
Breast J 13:130-9. 2007..Further study of a role for paxillin expression in predicting response to cytotoxic regimens or targeted treatments is warranted...- Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patientsDavid G Hicks
Department of Clinical and Anatomic Pathology, General Surgery-Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
Clin Cancer Res 12:6702-8. 2006..BRMS1 staining could potentially be used in patient stratification in conjunction with other prognostic markers. Further, mechanisms other than genomic deletion account for loss of BRMS1 gene expression in breast tumors... - A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institutionJoseph P Crowe
Department of General Surgery Breast Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 80, Cleveland, OH 44195, USA
Breast 15:728-35. 2006..Correlates of HER2 amplification were higher Scarff-Bloom-Richardson grade, younger age at diagnosis, and a comedo ductal carcinoma in situ component... - HER2-positive early breast cancer and trastuzumab: a surgeon's perspectiveSwati Kulkarni
Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Ann Surg Oncol 15:1677-88. 2008..If trastuzumab is approved for use in neoadjuvant regimens, the need for surgeons to be well informed about the appropriate use of this particular agent will become even more important... - An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanningRaymond R Tubbs
Departments of Anatomical and Clinical Pathology, The Cleveland Clinic Foundation, The Lerner College of Medicine, Cleveland, OH 44195, USA
J Mol Histol 38:141-50. 2007.... - The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical courseBrian J Yoder
Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Clin Cancer Res 11:186-92. 2005..If so, then fascin may represent a new molecular target for therapeutic intervention in patients with ER-negative breast cancer... - HER2 status in bilateral breast cancerJoseph P Crowe
Departments of General Surgery Breast Center, The Cleveland Clinic, Cleveland, Ohio 44195, USA
Int J Fertil Womens Med 51:219-23. 2006..The purpose of this study was to identify correlates of HER2 status for patients with bilateral breast cancer... - A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibilityWilliam C Powell
Ventana Medical Systems Inc, Tucson, AZ, USA
Appl Immunohistochem Mol Morphol 15:94-102. 2007..3% SI) in both cohorts. Interlaboratory reproducibility was also excellent (kappa 1.0). RMoAb 4B5 provides excellent sensitivity, specificity, and interlaboratory reproducibility for the detection of HER2 status in breast cancer... - The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization studyDavid G Hicks
Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Hum Pathol 36:348-56. 2005..If TOP2A gene dosage can be confirmed to correlate with tumor responsiveness to anthracycline-based therapy in the clinical setting, FISH testing for TOP2A status may be warranted to aid in the selection of the most appropriate therapy... - HER-2 testing in breast cancerRaymond R Tubbs
JAMA 292:1817-8; author reply 1818. 2004 - The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization studyErinn Downs-Kelly
Department of Anatomical and Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Am J Surg Pathol 29:1221-7. 2005..These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma... - The unmet clinical need for new molecular genetic markers in the prognosis and therapeutic management of breast cancerDavid G Hicks
Arch Pathol Lab Med 129:1372-4. 2005 - High-resolution immunophenotyping of subcellular compartments in tissue microarrays by enzyme metallographyRaymond Tubbs
Department of Anatomic and Clinical Pathology, The Cleveland Clinic Foundation, OH 44195, USA
Appl Immunohistochem Mol Morphol 13:371-5. 2005..This preliminary study shows the utility of using enzyme metallography for high-resolution immunophenotyping in TMAs... - Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelinesDavid G Hicks
Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Hum Pathol 36:250-61. 2005..The development of automated platforms for hybridization, image analysis for signal enumeration, and experience with FISH interpretation should broaden the availability of this technology for clinical diagnostic testing... - Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancerBrian Z Ring
Applied Genomics Inc, 863 Mitten Rd #103, Burlingame, CA, USA
J Clin Oncol 24:3039-47. 2006..CONCLUSION: A panel of five antibodies can significantly improve on traditional prognosticators in predicting outcome for ER-positive breast cancer patients... - Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivoAli Ghadersohi
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA
Breast Cancer Res Treat 102:19-30. 2007..Furthermore, loss of PDEF expression in breast cancer tissues tends to be associated with unfavorable prognosis. These studies provide new information for the role of PDEF and survivin in breast cancer cell growth and tumor formation... - Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFRDavid G Hicks
Clinical and Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
Am J Surg Pathol 30:1097-104. 2006.... - The role of the indispensable surgical pathologist in treatment planning for breast cancerDavid G Hicks
Arch Pathol Lab Med 132:1226-7. 2008 - Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility studyRaymond R Tubbs
Department of Anatomic and Clinical Pathology, The Cleveland Clinic Foundation and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA
Appl Immunohistochem Mol Morphol 14:436-40. 2006..Operational gains and enhanced consistency are inherent in this automated approach to HER2 clinical FISH testing... - Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experienceRaymond R Tubbs
Anatomic and Clinical Pathology, Cleveland Clinic Foundation and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
Diagn Mol Pathol 16:207-10. 2007..0 or more in at least 80% of tumor cells, was observed in 3% (20/742) of the cases. These data may be helpful as benchmarks for other institutions initiating primary FISH analysis for HER2 genotyping... - Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cellsKhalid Sossey-Alaoui
Roswell Park Cancer Institute, Department of Cancer Genetics, Elm and Carlton Streets, Buffalo, NY 14263, USA
Am J Pathol 170:2112-21. 2007..These studies provide direct evidence that the WAVE3-p38 pathway contributes to breast cancer progression and metastasis... - Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changesKen C Lo
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Genes Chromosomes Cancer 46:875-94. 2007..This genome wide screen provides an efficient and comprehensive survey of genes which potentially serve as the drivers for the CNAs in GBM...